Hope

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

Retrieved on: 
Friday, March 1, 2024

An estimated one in 10 people in the United States have a rare disease.

Key Points: 
  • An estimated one in 10 people in the United States have a rare disease.
  • The event recognized advocates who have been instrumental in building Utah’s rare disease community and have dedicated themselves to support this important work.
  • “There is an urgency for diagnoses, treatment and cures for the rare disease community,” said Gina Zanik, co-founder and executive director of Rare and Undiagnosed Network and Vice Chair of the Utah Rare Disease Advisory Council.
  • Rare disease patients came together at Recursion with the RARE and Undiagnosed Network (RUN), RARE-X , BioHive , ARUP Laboratories , BioUtah , the University of Utah and the Rare Disease Advisory Council (RDAC) for the Rare Disease Day event.

Stop & Shop Kicks Off 23rd Annual ‘Help Cure Childhood Cancer’ Campaign to Support MSK Kids, the Pediatric Program at Memorial Sloan Kettering Cancer Center

Retrieved on: 
Friday, March 1, 2024

NANUET, N.Y., March 01, 2024 (GLOBE NEWSWIRE) -- Today, Stop & Shop kicks off its annual ‘Help Cure Childhood Cancer’ campaign.

Key Points: 
  • NANUET, N.Y., March 01, 2024 (GLOBE NEWSWIRE) -- Today, Stop & Shop kicks off its annual ‘Help Cure Childhood Cancer’ campaign.
  • From March 1 – March 31, Stop & Shop customers in the tri-state area will be able to support MSK Kids, the pediatric program at Memorial Sloan Kettering Cancer Center (MSK).
  • The annual fundraiser, which celebrates its 23rd anniversary this year, raises money to support pediatric cancer care, treatment, and research.
  • “Memorial Sloan Kettering Cancer Center and MSK Kids remain grateful for Stop & Shop’s steadfast commitment to pediatric cancer research and care,” said Andrew Kung, MD, PhD, Chair of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center.

Foundation for Sarcoidosis Research Partners to Host 30 Volunteer Patient Leaders at Unique In-Person Training at Cleveland Clinic

Retrieved on: 
Friday, March 1, 2024

CHICAGO, March 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is honored to host its inaugural in-person training of FSR-GSCA Volunteer Patient Leaders from around the United States at Cleveland Clinic, the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Founding Member.

Key Points: 
  • CHICAGO, March 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is honored to host its inaugural in-person training of FSR-GSCA Volunteer Patient Leaders from around the United States at Cleveland Clinic, the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Founding Member.
  • This inaugural in-person training of FSR-GSCA Volunteer Patient Leaders has been structured to empower volunteer patient leaders with the skills, knowledge, and connections necessary to make a meaningful impact in the fight against sarcoidosis.
  • Cleveland Clinic is a proud member of the FSR Global Sarcoidosis Clinic Alliance and is honored to hold this training event in collaboration with FSR.
  • For media inquiries or more information about the FSR-GSCA Patient Volunteer Leaders’ Training Event, please contact [email protected] .

Briggs & Riley and Comfort Cases Continue Partnership to Support Youth in Foster Care

Retrieved on: 
Friday, March 1, 2024

Starting today, and running throughout the month of March, Briggs & Riley customers can directly help youth in and entering foster care by participating in the “Buy a Bag, Give a Bag” promotion.

Key Points: 
  • Starting today, and running throughout the month of March, Briggs & Riley customers can directly help youth in and entering foster care by participating in the “Buy a Bag, Give a Bag” promotion.
  • For every order of $99 or more placed on Briggs-Riley.com , a new duffle bag will be donated to Comfort Cases.
  • Comfort Cases takes each bag and fills them with never-used essential items for youth entering the foster care system, including: new pajamas, a blanket, a towel, a hygiene kit (soap, shampoo, conditioner, etc.
  • Each Comfort Case™ backpack also comes with a Comfort XL Duffle bag (retail $150) also provided by Briggs & Riley.

Stop & Shop Fights Pediatric Cancer with Kick Off of ‘Help Cure Childhood Cancer’ Campaign

Retrieved on: 
Thursday, February 29, 2024

Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.

Key Points: 
  • Stop & Shop’s ‘Help Cure Childhood Cancer’ campaign will run in all stores from March 1 through March 31.
  • 100% of proceeds will benefit the two hospitals to assist in their pioneering pediatric cancer treatment and care.
  • The Stop & Shop Pediatric Brain Tumor Clinic at Dana-Farber Cancer Institute is a world-renowned destination for children with malignant and non-malignant brain tumors.
  • “Stop & Shop’s dedication and generous support of pediatric cancer continues to help fund critical research and care,” said Scott Armstrong, MD, PhD, chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute.

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS

Retrieved on: 
Thursday, February 29, 2024

The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .

Key Points: 
  • The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program .
  • ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.
  • Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe.
  • With this funding and invaluable support from the ALS Association, we are poised to move our CTx-TFEB program forward.

Cemtrex Issues Shareholder Letter and Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024

To the Shareholders of Cemtrex, Inc.,

Key Points: 
  • To the Shareholders of Cemtrex, Inc.,
    I wanted to provide you with a detailed update on Cemtrex’s activities over the last several months.
  • We cannot change the missteps we have taken, but we have certainly learned from them and learned how to avoid them in the future.
  • Private companies have certain luxuries that public companies do not have when it comes to building startups, particularly in rising interest rate environments.
  • Out of that purchase price, Cemtrex contributed $1,000,000 of equity, which was paid in the form of Cemtrex stock.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Retrieved on: 
Wednesday, February 28, 2024

Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.

Key Points: 
  • Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production.
  • We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
  • By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together.
  • As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place.

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia. The NDA was granted Priority Review status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024. The FDA also noted that it is planning to hold an advisory committee meeting to discuss the application. Govorestat was previously granted Pediatric Rare Disease designation, and will qualify for a Priority Review Voucher (PRV) upon approval.

Key Points: 
  • The NDA was granted Priority Review status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024.
  • Govorestat was previously granted Pediatric Rare Disease designation, and will qualify for a Priority Review Voucher (PRV) upon approval.
  • “The FDA’s acceptance of the NDA for govorestat for the treatment of Galactosemia represents a critical milestone for Applied Therapeutics and more importantly, for patients with Galactosemia and their families.
  • If approved, govorestat would be the first medication indicated for the treatment of Galactosemia and would be Applied Therapeutics’ first commercial product.

BY WAY OF YOUR HEART is a Poetic Journey From Grief to Healing

Retrieved on: 
Wednesday, February 28, 2024

For her, every word on the page is a chance to embody her story and share it with others.

Key Points: 
  • For her, every word on the page is a chance to embody her story and share it with others.
  • By Way of Your Heart is a distillation of the emotional essence of life—and of relational bonds that Priscilla says transcend life and death.
  • It explores the ways we use fantasy not only as escapism but as a genuine place of comfort and peace.
  • It will be a treasured read for anyone who enjoys poetry with emotional breadth, a commitment to both truth and hope and a deeply personal touch.